Can gliclazide be used for pre‑gestational diabetes control in a woman planning pregnancy?

Gliclazide Should NOT Be Used for Pre-Pregnancy Diabetes Control

Gliclazide (and all sulfonylureas) must be discontinued before conception in women planning pregnancy, with insulin being the preferred antidiabetic medication during the preconception period and throughout pregnancy. 1

Why Gliclazide Is Contraindicated

The FDA drug label for glipizide (gliclazide's class equivalent) explicitly states that "many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible" due to the association between abnormal blood glucose levels during pregnancy and higher incidence of congenital abnormalities 1.

Key Safety Concerns:

Fetal Toxicity and Neonatal Hypoglycemia:

• Sulfonylureas demonstrate mild fetotoxicity in animal studies at all dose levels
• Prolonged severe hypoglycemia (4-10 days) has been reported in neonates born to mothers receiving sulfonylureas at delivery
• This risk is particularly concerning with agents having prolonged half-lives 1

Timing of Discontinuation:

• If gliclazide has been used, it must be discontinued at least one month before the expected delivery date
• For preconception planning, discontinuation should occur well before attempting conception 1

What Should Be Used Instead

Insulin is the gold standard for pre-pregnancy diabetes control 2, 3. The 2025 Endocrine Society/European Society of Endocrinology joint guideline explicitly recommends insulin as the preferred antidiabetic medication in pregnancy 2.

Metformin may be considered as an adjunct in specific situations:

• The 2025 guidelines note that metformin use in pregnancies with T2DM has been steadily increasing 2
• However, metformin is not a substitute for insulin in T2DM as it can be in gestational diabetes, since women with pre-existing T2DM have more severe insulin deficiency and resistance 2
• Important caveat: Metformin crosses the placenta extensively and has been associated with potential fetal growth restriction and long-term metabolic programming concerns 2

Clinical Algorithm for Pre-Pregnancy Diabetes Management

1. Immediate assessment: If patient is on gliclazide and planning pregnancy, transition to insulin immediately
2. Contraception: Use effective contraception until glycemic goals are achieved on insulin 2
3. Glycemic targets: Achieve HbA1c as close to normal as possible before conception (ideally <6.5% if achievable without significant hypoglycemia) 3
4. Monitoring: Implement intensive glucose monitoring with either CGM or frequent SMBG 3
5. Preconception care: Screen for pregnancy intention at every visit and provide comprehensive preconception counseling 4

Limited Research Evidence Does Not Override Safety Concerns

While one small observational study (n=108) suggested gliclazide use during pregnancy was not associated with increased adverse outcomes compared to metformin 5, this very limited evidence cannot override:

• Clear FDA warnings about sulfonylurea use in pregnancy
• Known mechanisms of fetal harm
• Documented cases of neonatal hypoglycemia
• The availability of safer, evidence-based alternatives (insulin)

Common Pitfall: Do not be tempted to continue gliclazide based on small case series or individual case reports 6. The absence of observed harm in limited cases does not establish safety, particularly when safer alternatives exist.